Landos Biopharma, Inc. (NASDAQ:LABP - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for shares of Landos Biopharma in a research note issued on Monday, April 1st. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of ($0.88) for the quarter. HC Wainwright currently has a "Neutral" rating and a $20.42 target price on the stock. The consensus estimate for Landos Biopharma's current full-year earnings is ($2.03) per share. HC Wainwright also issued estimates for Landos Biopharma's Q2 2024 earnings at ($0.63) EPS, Q3 2024 earnings at ($0.48) EPS, Q4 2024 earnings at ($0.53) EPS, FY2024 earnings at ($2.35) EPS and FY2025 earnings at ($2.07) EPS.
Landos Biopharma Price Performance
LABP stock traded down $0.03 during trading on Wednesday, hitting $21.49. The stock had a trading volume of 25,034 shares, compared to its average volume of 22,726. Landos Biopharma has a twelve month low of $2.50 and a twelve month high of $21.87. The stock has a market capitalization of $67.05 million, a P/E ratio of -6.21 and a beta of 0.14. The company's 50-day moving average price is $8.45 and its two-hundred day moving average price is $5.58.
Institutional Trading of Landos Biopharma
Several institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. raised its position in Landos Biopharma by 119.1% in the second quarter. Goldman Sachs Group Inc. now owns 42,800 shares of the company's stock valued at $31,000 after purchasing an additional 23,263 shares during the period. HRT Financial LP acquired a new position in Landos Biopharma during the fourth quarter worth $26,000. Bank of America Corp DE lifted its stake in Landos Biopharma by 80.4% during the first quarter. Bank of America Corp DE now owns 56,321 shares of the company's stock worth $83,000 after purchasing an additional 25,096 shares in the last quarter. Vanguard Group Inc. lifted its stake in Landos Biopharma by 30.6% during the third quarter. Vanguard Group Inc. now owns 166,608 shares of the company's stock worth $108,000 after purchasing an additional 39,053 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Landos Biopharma by 99.0% during the first quarter. Renaissance Technologies LLC now owns 340,500 shares of the company's stock worth $502,000 after purchasing an additional 169,400 shares in the last quarter. Hedge funds and other institutional investors own 49.06% of the company's stock.
Landos Biopharma Company Profile
(
Get Free Report)
Landos Biopharma, Inc, a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract.
See Also
Before you consider Landos Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Landos Biopharma wasn't on the list.
While Landos Biopharma currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
